IOP Reduction After Anecortave Acetate Injection in Glaucoma Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Introduction: Ocular administration of glucocorticoids is a common and effective treatment
for several ocular diseases. However it is often complicated with the elevation of
intraocular pressure (IOP). Anecortave acetate (AA) is an analog of cortisol acetate and
lacks the typical anti-inflammatory and immunosuppressive properties of glucocorticoids. The
effect of its anterior juxtascleral depot (AJD) injection has been evaluated in cases of
glaucoma caused by intravitreal triamcinolone acetonide, presenting impressive results. The
purpose of this study is to evaluate the efficacy and safety of the AA injection as a
possible antiglaucoma treatment alternative. Methods: A prospective clinical study will be
carried out including 30 glaucoma patients (30 eyes). After inclusion each patient will
receive a single AJD injection of 30 mg of AA in the selected eye. Main outcome measure
include: intraocular pressure at 1st day, 7th day, 1st, 2nd and 3rd months.